Bain Capital & AbbVie

Bain Capital: Bain Capital, as Coeptis Therapeutics Holdings' controlling shareholder, is accused of acquiring Coeptis Therapeutics Holdings shares at an artificially depressed price while allegedly possessing material nonpublic information about AbbVie Inc.'s acquisition interest, resulting in a significant windfall.

AbbVie: AbbVie Inc. is implicated in the lawsuit for its alleged undisclosed interest in acquiring Coeptis Therapeutics Holdings at a higher price than the secondary offering, which supposedly led to an artificially deflated stock price for Coeptis Therapeutics Holdings.

Bain Capital: Bain Capital, Coeptis Therapeutics Holdings's controlling shareholder, acquired shares at an allegedly artificially depressed price during the October Offering while in possession of material nonpublic information about AbbVie Inc.'s interest, leading to a $120 million windfall.

AbbVie: AbbVie Inc. agreed to acquire Coeptis Therapeutics Holdings for $45 per share, a price significantly higher than Coeptis Therapeutics Holdings's secondary offering price, which is central to the alleged securities fraud.

Bain Capital: Bain Capital, LP is accused of orchestrating a secondary stock offering of Coeptis Therapeutics Holdings at a deeply discounted price, allowing it to increase its position before the undisclosed acquisition by AbbVie Inc., resulting in a $120 million windfall.

AbbVie: AbbVie Inc. acquired Coeptis Therapeutics Holdings for $45 per share, an acquisition that was allegedly undisclosed during Coeptis Therapeutics Holdings's secondary stock offering, leading to a windfall for Bain Capital, LP.